OUTLINE
1. Immutep
2. Notice: Forward Looking Statements
3. Eftilagimod Alpha (efti or IMP321)
4. Targeting LAG-3 / MHC II may lead to multiple therapeutics i…
5. Immutep Controlled Immunotherapy Pipeline (Oncology)*
6. Efti: an innovative LAG-3 I-O product candidate
7. Efti: a pipeline in a product
8. AIPAC update
9. Efti: Clinical Development AIPAC (Phase IIb)
10. Efti positioning in HR+/HER2- MBC
11. Recent MBC approvals and late stage approaches: Selected …
12. Combining efti and anti-PD-1: TACTI-002
13. Rationale for combining efti with PD-1 antagonists
14. Efti: Clinical Development TACTI-002 (Phase II)
15. Efti: Clinical Development TACTI-002 - Safety
16. Efti: Clinical Development TACTI-002 - 1st line NSCLC (Part A)
17. Efti: Clinical Development TACTI-002 - 1st line NSCLC (Part …
18. Efti: Clinical Development TACTI-002 - 1st line NSCLC (Part …
19. Efti: Clinical Development TACTI-002 - 2nd line HNSCC (Part…
20. Comparables and Outlook
21. Efti: Clinical Development TACTI-002 (Phase II)
22. Efti: a pipeline in a product
23. Q&A
0000000000000000
(ASX: IMM, NASDAQ: IMMP)
Immutep TACTI-002 Clinical Results & Update
 Global Webcast Slides
Immutep will present these slides as part of its global webcast, as follows:
Date & Time:    Wednesday, February 26, 2020, 8:00 am Australian Eastern Daylight Time /
              Tuesday, February 25, 2020, 4:00 pm US Eastern Standard Time
 
Register:          Interested parties can join the webcast by registering via FNN. 
 
A replay of the webcast will also be available at www.immutep.com from the day after the event.
000000000000000000000000000000000000000000000000